Genmab opened higher at $57.40, compared with its previous close of $56.49. In the last trading session, the stock traded between $57.14 and $59.02. It showed an upward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Genmab is now worth
$ 130.32
giving a profit of
$ 30.32 (30.32%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
90%
Hold
10%
Sell
0%
Markets Today
Today's Change
+$1.69 (+2.98%)
Day High
$59.02
Day Low
$57.14
Day Open
$57.40
Prev Close
$56.49
Volume
28,38,522
1W Return
45.44%
1M Return
63.57%
3M Return
104.02%
6M Return
122.81%
1Y Return
100.95%
Fundamentals
Market Cap ($ Mn)
36,305
PE Ratio
26.24
PB Ratio
3.43
PEG Ratio
1.70
ROE
17.62%
ROCE
16.07%
EPS (TTM)
$4.93
Investment Returns
1 Week
45.44%
1 Month
63.57%
3 Months
104.02%
6 Months
122.81%
9 Months
74.44%
Financials
Quarterly
All values in $ Mn
923.8
Dec 24
715.0
Mar 25
925.0
Jun 25
1.0K
Sep 25
1.1K
Dec 25
1.2K
Jun 26
Updates
5Oct
Genmab Rina-S posts 45.9% ORR in platinum-resistant ovarian cancer
Genmab's Rina-S showed a 45.9% objective response rate in platinum-resistant ovarian cancer. Median duration of response was 12.1 months at a dose of 120 mg/m² every three weeks. Antitumor activity was observed regardless of folate receptor alpha expression levels.
25 days ago
7Aug
Genmab raises FY2026 sales guidance to $4.325B-$4.525B vs estimate
Genmab upgraded its full-year 2026 revenue outlook to $4.325 billion–$4.525 billion, exceeding analyst estimates, supported by strong H1 results showing 25% revenue growth to $2,051 million and rising adjusted operating profit.
2mo ago
23Jul
TD Cowen upgrades Genmab to Buy, raises target to $43
TD Cowen analyst Yaron Werber upgraded Genmab from Hold to Buy and raised the price target from $32 to $43, signaling a positive shift in the stock's outlook. The new target suggests significant upside potential.
3mo ago
2Jul
HC Wainwright raises Genmab price target to $40
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Genmab (NASDAQ: GMAB) and raises the price target from $38 to $40, signaling confidence in the biotechnology company's future performance.
4mo ago
23Jun
HC Wainwright reiterates Buy on Genmab, maintains $38 target
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating for Genmab, maintaining a price target of $38. The reiteration signals ongoing confidence in the stock's prospects.
